AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Pro Medicus sees double-digit growth in early 2025
- Healthcare tech shines amid global sector momentum
- PME valuation reflects rising demand for radiology software
Pro Medicus Ltd (ASX:PME), a leading name in medical imaging software, has continued its impressive trajectory in 2025, with its share price rising 10.8% since the beginning of the year. As part of the broader healthcare landscape and a constituent of the ASX300 index, the company’s momentum reflects larger trends in both sector demand and technology-driven healthcare innovation.
Pro Medicus specialises in radiology software that serves hospitals, imaging centres, and healthcare networks globally. Its suite of solutions—including Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation tools—supports a seamless workflow from patient scheduling and billing to diagnostic imaging interpretation.
One of the standout offerings from the company is its Visage software. Designed to allow radiologists to access and interpret large imaging files remotely, even on mobile devices, this tool enhances speed and flexibility in diagnostics. In an age where rapid decision-making is critical in healthcare, such features offer clear operational advantages.
The healthcare sector has historically demonstrated resilience, with spending patterns largely shielded from economic cycles. This stability can be attributed to the essential nature of medical services. During times of financial uncertainty, healthcare often remains a priority, making companies in this space particularly resilient. Historically, the sector also outperformed during downturns, including during the Global Financial Crisis.
Looking ahead, global healthcare spending—especially in the United States, which comprises over 40% of the global total—is forecast to rise significantly. Estimates project 7% annual growth from 2022 to 2027, hitting US$819 billion. Furthermore, sub-sectors like healthcare IT and software-as-a-service (SaaS) are expected to grow even faster, at rates exceeding 15% annually through to 2030.
Increased focus on ethical and sustainable investment strategies is also drawing attention to companies like Pro Medicus, which operate within essential service industries. Healthcare firms offering real-world impact and technological innovation are increasingly aligning with investor preferences for sustainable and socially responsible options, a factor contributing to their appeal in modern portfolios.
It’s worth noting that Pro Medicus (PME) currently trades at a price-to-sales ratio of 180.75x, which is significantly higher than its 5-year average of 82.69x. This elevated valuation aligns with continued revenue growth over recent years, though context is essential when interpreting such metrics.
As interest in sectors offering resilient revenue models and innovation continues to rise, Pro Medicus remains a standout in both the ASX300 and healthcare tech space. For those tracking sector performance or seeking exposure to ASX dividend stocks, healthcare companies like PME offer an interesting intersection of stability and technological edge.
